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Aims Effective prevention of recurrent pericarditis remains an important yet elusive
goal. Corticosteroid therapy often needs to be continued for a prolonged period and
causes severe side effects. We performed a multi-centre all-case analysis to investi-
gate the efﬁcacy of colchicine in preventing subsequent relapses of pericarditis,
and addressed the hypothesis that pretreatment with corticosteroids may attenuate
the beneﬁcial effect of colchicine.
Methods and results One hundred and forty published and unpublished cases of
patients treated with colchicine after at least two relapses of pericarditis were
aggregated from European centres. Of those, 119 were included in the study group.
Only 18% of the patients had relapses under colchicine therapy, and 30% after its
discontinuation. There were signiﬁcantly more relapses among male patients after
colchicine treatment (36 vs. 17%, P ¼ 0.046), and those with previous corticosteroid
treatment (43 vs. 13%, P ¼ 0.02). Multivariate logistic regression analysis identiﬁed
previous corticosteroid therapy (OR 6.68, 95% CI: 1.65–27.02) and male gender
(OR 4.20, 95% CI: 1.16–15.21) as independent risk factors for recurrence following
colchicine therapy.
Conclusion Treatment with colchicine is highly effective in preventing recurrent peri-
carditis, while pretreatment with corticosteroids exacerbates and extends the course
of recurrent pericarditis.
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Introduction
Effective prevention of recurrent pericarditis remains
an important yet elusive goal.1–3 Therapeutic approaches
have traditionally includednon-steroidal anti-inﬂammatory
drugs (NSAIDs), corticosteroids, immunosuppressive
agents, and, in unremitting cases, pericardiectomy.1–3
Because relapses may occur during attempts to reduce
drug dose, corticosteroid therapy, once initiated, often
needs to be continued for a prolonged period of time,
and is therefore fraught with severe side effects.2–5
Moreover, clinical observations have raised the suspicion
that corticosteroid use may actually prolong attacks
and predispose to further recurrences.5 For the treatment
of acute pericarditis the use of corticosteroids is rec-
ommended only as a last resort for severe resistant cases.6
Colchicine, a unique anti-inﬂammatory agent that was
introduced for the therapy of acute gout in 1763,7 pro-
vides dramatic relief from acute inﬂammatory attacks,
in addition to acting as a prophylactic agent for the
chronic pattern.7 It was ﬁrst proposed for the treatment
of recurrent pericarditis in 1987 by Rodriguez de La Serna
et al.,8 based on its proven efﬁcacy to prevent relapses
of polyserositis in familiar Mediterranean fever. In
1990, Guindo et al.9 published the ﬁrst clinical study
supporting the efﬁcacy of colchicine in preventing
recurrences of pericarditis. To date, several small non-
randomized studies and case reports have corroborated
the efﬁcacy and safety of colchicine in the management
of recurrent pericarditis.10–25 In the absence of a ran-
domized, placebo-controlled trial, as proposed by The
Taskforce of Pericardial Disease of the World Heart
Federation,26 we sought to aggregate all published and
unpublished data available on the outcome of patients
with recurrent pericarditis treated with colchicine.
Employing this multi-centre all-case approach, a data-
base of 119 cases was created. We then investigated
the inﬂuence of predeﬁned clinical variables on the
efﬁcacy of colchicine in preventing subsequent relapses
of pericarditis in a multivariable logistic regression
model. In particular, we addressed the hypothesis that
pretreatment with corticosteroids may attenuate the
beneﬁcial effect of colchicine in patients with recurrent
pericarditis.
Methods
The study was designed as a multi-centre all-case analysis.
Researchers who published studies and case reports on colchi-
cine treatment in recurrent pericarditis during the last 15
years were approached and asked to contribute all available
cases to the database. Patient’s data were obtained from
Italy (n ¼ 44), France (n ¼ 37), Spain (n ¼ 33), Israel (n ¼ 20),
Lebanon (n ¼ 3), Turkey (n ¼ 2), and Denmark (n ¼ 1).
A total of 140 cases (99 patients from published studies and
case reports, and 41 so far unpublished cases) were screened
to match the following inclusion criteria:
(i) clinical diagnosis of two or more relapses of acute
pericarditis;
(ii) therapeutic trial of colchicine beyond its use during the
tapering period of corticosteroids or NSAID;
(iii) complete documented follow-up since the ﬁrst episode of
acute pericarditis, including reports on therapeutic trials
with corticosteroids, and continuing for at least 1 month
following initiation of colchicine therapy.
In particular, data were considered complete only in patients
with a methodical follow-up since ﬁrst relapse of pericarditis,
that included precise information about the following predeﬁned
clinically relevant variables: age, sex, etiology of pericarditis,
duration of follow-up since ﬁrst relapse of pericarditis, use of
corticosteroid therapy, number or relapses before initiation of
colchicine treatment, and duration of colchicine treatment,
and duration of follow-up after discontinuation of colchicine
treatment. In addition, precise information needed to be docu-
mented about the number of relapses during colchicine treat-
ment as well as during follow-up after discontinuation of
colchicine treatment (post-colchicine).
Twenty-one patients had to be excluded, 13 patients were
lacking deﬁnitive age data, 6 patients were treated with a
colchicine dose different from 1 mg/day for a prolonged period
(to achieve homogeneity of treatment), and 2 patients had
been followed-up for ,1 month; no patient was reported
dead. The remaining 119 patients represent the study group,
78 of whom were male (65%) and 41 were female (35%),
ranging in age from 8 to 83 years (44+ 18 years).
Follow-up from the instituting of colchicine therapy ranged
from 1 to 185 months. In 88 patients (74%), colchicine therapy
was discontinued during follow-up and renewed only in case of
relapse. In these patients, the total length of treatment was
summed up for analysis. Thirty-one patients (26%) were taking
colchicine as a permanent treatment and no colchicine-free
follow-up was documented; in four patients (3.4%) follow-up
after colchicine treatment lasted for only 1 month.
Statistical methods
Results were expressed as mean value +SD. Comparison
between groups was performed by x2 test or Fisher’s exact
test for categorical variables and by t-test for continuous vari-
ables. The predeﬁned clinically variables were tested for corre-
lation, by Pearson correlation, with the number of relapses after
colchicine therapy. Variables, for which a signiﬁcant relationship
was found, were then entered into a multivariable logistic
regression analysis (forward likelihood ratio) to identify indepen-
dent risk factors for relapses. The statistical model derived was
validated using the Hosmer–Lemeshow test yielding a test stat-
istics of 6.56, P ¼ 0.585. Results were expressed as OR and 95%
CI. P-value ,0.05 was considered signiﬁcant.
Results
While all patients had experienced recurrences before
treatment with colchicine, only 18% of patients (21/119)
had relapses during colchicine treatment, and 30% (26/
88) after its discontinuation. Relapses occurred
signiﬁcantly more among men than women (36 vs. 17%,
P ¼ 0.058) after discontinuation of colchicine therapy
(Figure 1 ). Corticosteroids were administered to 60% of
patients prior to initiation of colchicine treatment. The
percentage of patients with relapses before, during, and
after colchicine treatment in the respective groups is pre-
sented in Figure 2. In patients with previous corticosteroid
treatment, a signiﬁcantly higher number of patients had
recurrence after colchicine treatment (43 vs. 13%,
P ¼ 0.02). Comparing the data for those treated with
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and without corticosteroids (Table 1 ) reveals that the dur-
ation of colchicine treatment was signiﬁcantly longer
(24.4+ 23.3 vs. 9.7+ 7.8, P ¼ 0.001), and the average
number of relapses per patient after colchicine treatment
was signiﬁcantly higher (0.65+ 0.99 vs. 0.18+ 0.56,
P ¼ 0.006) among those with previous corticosteroid
treatment. No differences were found between the two
groups regarding the average number of relapses per
patient during colchicine treatment. Table 2 details the
partial correlations between the number of relapses in
each period and the duration of follow-ups and treatment,
controlling for age.
As expected, there was a signiﬁcant correlation
between duration of follow-up and number of relapses
before colchicine treatment (r ¼ 0.63, P, 0.01).
No correlation was found between duration of colchicine
treatment and number of relapses before colchicine trea-
tment.There was no correlation between the numbers of
relapses in each period of follow-up; in particular, there
was no correlation between the numbers of relapses
before colchicine treatment and the number of relapses
under colchicine treatment, or after its discontinuation.
When entering the ﬁve variables for which a signiﬁcant
correlation with the number of relapses after colchicine
therapy was found—age, gender, previous corticosteroid
therapy, duration of treatment, and follow-up into a mul-
tivariable logistic regression analysis, only corticosteroid
and male gender treatment emerged as independent
predictors for recurrences (Table 3 ). The OR for previous
corticosteroid therapy was 6.68 (95% CI: 1.65–27.02,
P ¼ 0.008) and for male gender 4.2 (95% CI:
1.16–15.21, P ¼ 0.029).
In almost 70% of the patients, no speciﬁc etiology of
pericarditis could be identiﬁed. The other etiologies
were identiﬁed as s/p pericardiectomy (16%), s/p myo-
cardial infarct (7.6%), familial Mediterranean fever
(3.4%), systemic lupus erythematosus (1.7%), rheumatoid
arthritis (0.8%), and sjogren’s syndrome (0.8%). A viral
infection was conﬁrmed only in two patients (1.7%).
Discussion
The present multi-centre all-case analysis of the largest
database so far demonstrates that colchicine therapy
is highly effective in preventing recurrences of acute
pericarditis. The results are particularly encouraging,
because the study included only patients with at least
two previous relapses, thus focusing on a group that rep-
resents a major therapeutic challenge. As hypothesized,
the proportion of patients with relapses during or after
colchicine therapy was signiﬁcantly higher in the group
of patients treated with corticosteroids in the past.
Moreover, duration of colchicine therapy was signiﬁcantly
longer (P ¼ 0.001) in patients pretreated with corticos-
teroids (24.5 months) than in those who were not (9.7
months). Although these patients had signiﬁcantly more
relapses before institution of colchicine therapy than
patients who had not received corticosteroids in the
past (Table 1 ), the question arises whether past corticos-
teroid use may be simply a marker of a higher tendency
to relapse, rather than a cause of it.
However, the lack of correlation between the number
of relapses before colchicine therapy and the number
of relapses during, or following colchicine therapy
(Table 2 ) supports the view that corticosteroid therapy
itself is associated with a higher tendency to relapse. In
fact, logistic multivariable analysis identiﬁed pretreat-
ment with steroids as the most powerful independent
predictor of relapse following colchicine therapy, carrying
an almost seven-fold increased risk (OR 6.68, P ¼ 0.008) on
average (Table 3 ). The second independent predictor of
relapse was male gender (OR 4.2, P ¼ 0.029).
Figure 1 Gender difference in the percentage of patients with relapse
during the treatment with colchicine and after its discontinuation. Dark
grey, female; light grey, male.
Figure 2 Differences in the percentage of patients with relapses during
the treatment with colchicine and after its discontinuation as a function
of a previous corticosteroid treatment. Dark grey, with corticosteroids;
light grey, without corticosteroids.
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The fact that most of the patients studied were from
Mediterranean countries gives rise to the question of
whether recurrent pericarditis occurred as a symptom
of familiar Mediterranean fever.27,28 However, only four
patients (3.4%) were diagnosed with this disease, while
pericarditis was considered idiopathic in almost 70% of
the study group. A further investigation of the idiopathic
cases would presumably reveal either viral or auto-
immune etiologies.29,30
While all patients showed relief of signs and
symptoms under colchicine therapy, 18% (21/119)
of the patients had new relapses under colchicine
treatment. Considering the natural course of the
disease, characterized by periodic relapses,3 it might
have been expected that patients would experience
new recurrences after discontinuation of the therapy.
However, during a mean follow-up period of over 2
years, 70% of the patients (62/88) in whom colchicine
was discontinued remained free from new relapses.
The absence of a correlation between the number
of relapses per patient in the different periods of
follow-up (before, during, and post colchicine) supports
the concept that colchicine therapy provides
sustained beneﬁt even after discontinuation of the drug.
Study limitations
The present study is an analysis of patients with
recurrent pericarditis with substantial variation in the
number of previous relapses (from 2 to 45 episodes),
the timing of instituting colchicine therapy (from 1 to
228 months following the ﬁrst episode) as well as treat-
ment duration (from 1 to 128 months, with 26% of the
patients receiving colchicine permanently). On the
other hand, such variation represents the full spectrum
of clinically relevant presentations of recurrent pericar-
ditis. In order to approach homogeneity with respect to
the treatment protocol, only patients who were treated
with a conventional dose of 1 mg of colchicine per day,
which combines high efﬁcacy with a low prevalence of
side effects,8–9 were included in the analysis. Every
Table 1 Comparison between the number of relapses, duration of follow-up, and colchicine treatment in patients with and without
previous corticosteroid treatments
Corticosteroid
treatment
No corticosteroid
treatment
T P-value
n Mean SD n Mean SD
Follow-up before colchicine treatment (in months) 71 19.3 33.9 48 14.2 29.9 0.85 0.396
No. of relapses per patient before treatment
(including ﬁrst episode)
71 5.10 5.70 48 2.81 1.02 3.30 0.001
Treatment with colchicine (in months) 71 24.5 23.3 48 9.7 7.8 4.50 0.001
No. of relapses per patient under colchicine 71 0.46 1.45 48 0.19 0.53 1.47 0.145
Follow-up post colchicine (in months) 49 47.6 39.1 39 26.1 18.9 3.35 0.001
No. of relapses per patient post colchicine 49 0.65 0.99 39 0.18 0.56 2.83 0.006
Table 2 Partial correlation between the number of relapses per patient and duration of follow-up and treatment, controlling
for age
Duration of
follow-up
before
No. of
relapses
before
Duration of
treatment
No. of
relapses
during
Duration of
follow-up
post
No. of
relapses
post
Duration of follow-up before colchicine 1 0.63 0.07 20.01 0.18 0.16
No. of relapses per patient before 1 0.14 0.11 0.22 0.08
Duration of treatment with colchicine 1 0.20 20.16 0.06
No. of relapses per patient during colchicine 1 20.06 20.03
Duration of follow-up post colchicine 1 0.17
No. of relapses post colchicine 1
P, 0.01
Table 3 Logistic regression for predicted relapses after
colchicine treatment
Variable OR 95% C.I. P-value
Male gender 4.20 1.16–15.21 0.029
Age (5 years) 0.90 0.76–1.11 0.237
Previous corticosteroids
treatment
6.68 1.65–27.02 0.008
Treatment duration
(6 months)
1.13 0.91–1.39 0.278
Follow-up after colchicines
treatment (3 months)
0.96 0.91–1.01 0.174
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attempt was made to include unpublished cases in this
multi-centre all-case analysis to avoid publication bias,
yet by its very nature this is difﬁcult to ascertain
completely.
Ultimately, only a randomized placebo-controlled
double-blind trial may provide a deﬁnitive answer to
the question of optimal therapy for recurrent pericardi-
tis. However, in the absence of such a study, the analysis
of the present large database provides an important
source of information for guiding the treatment of this
problematic patient group.
Conclusions
Pretreatment with corticosteroids attenuates the efﬁ-
cacy of colchicine in preventing recurrent pericarditis,
exacerbating and extending its course. Colchicine is
highly effective in preventing new relapses in patients
with recurrent pericarditis. Because of the increased
risk of recurrences and the severe side effects of pro-
longed corticosteroids therapy on one hand, and the
favourable efﬁcacy and the few side effects of colchicine
on the other hand, we consider colchicine in a dose of
1 mg/day as the ﬁrst-line drug of choice for recurrent
pericarditis.
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